These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study. Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840 [TBL] [Abstract][Full Text] [Related]
45. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Natarajan JV; Ang M; Darwitan A; Chattopadhyay S; Wong TT; Venkatraman SS Int J Nanomedicine; 2012; 7():123-31. PubMed ID: 22275828 [TBL] [Abstract][Full Text] [Related]
46. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568 [TBL] [Abstract][Full Text] [Related]
47. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Higginbotham EJ; Diestelhorst M; Pfeiffer N; Rouland JF; Alm A Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S133-40. PubMed ID: 12204710 [TBL] [Abstract][Full Text] [Related]
48. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension. Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229 [TBL] [Abstract][Full Text] [Related]
49. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range. Varma R; Hwang LJ; Grunden JW; Bean GW; Sultan MB Am J Ophthalmol; 2009 Aug; 148(2):221-6. PubMed ID: 19427617 [TBL] [Abstract][Full Text] [Related]
50. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma. Wang Y; Liao Y; Nie X Clinics (Sao Paulo); 2020; 75():e1874. PubMed ID: 33263632 [TBL] [Abstract][Full Text] [Related]
51. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Liu JH; Kripke DF; Weinreb RN Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220 [TBL] [Abstract][Full Text] [Related]
52. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241 [TBL] [Abstract][Full Text] [Related]
53. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480 [TBL] [Abstract][Full Text] [Related]
54. Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study. Kobayashi H J Ocul Pharmacol Ther; 2012 Jun; 28(3):245-50. PubMed ID: 22283238 [TBL] [Abstract][Full Text] [Related]
55. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111 [TBL] [Abstract][Full Text] [Related]
56. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery. Maulvi FA; Lakdawala DH; Shaikh AA; Desai AR; Choksi HH; Vaidya RJ; Ranch KM; Koli AR; Vyas BA; Shah DO J Control Release; 2016 Mar; 226():47-56. PubMed ID: 26860285 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Shin DH; Feldman RM; Sheu WP; Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375 [TBL] [Abstract][Full Text] [Related]
58. Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol. Bron AM; Denis P; Nordmann JP; Rouland JF; Sellem E; Johansson M Acta Ophthalmol Scand; 2001 Jun; 79(3):289-93. PubMed ID: 11401641 [TBL] [Abstract][Full Text] [Related]
59. The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure. Özyol E; Özyol P J Glaucoma; 2016 Feb; 25(2):135-9. PubMed ID: 25264990 [TBL] [Abstract][Full Text] [Related]
60. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. Lee JW; Ahn HS; Chang J; Kang HY; Chang DJ; Suh JK; Lee H Korean J Ophthalmol; 2022 Oct; 36(5):423-434. PubMed ID: 35989070 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]